Tylenol maker Kenvue ousts CEO amid board's strategic review
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 14 2025
0mins
Source: Reuters
Executive Changes at Kenvue: Kenvue has fired CEO Thibaut Mongon amid investor pressure for improved performance, appointing Kirk Perry as interim CEO while also considering portfolio simplification and potential divestitures.
Financial Outlook and Strategic Review: The company is reviewing its operations with the help of advisors to evaluate possible sales of underperforming brands, particularly in its skin-health and beauty unit, and anticipates second-quarter profits aligning with analyst estimates.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KVUE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KVUE
Wall Street analysts forecast KVUE stock price to rise
8 Analyst Rating
1 Buy
7 Hold
0 Sell
Hold
Current: 18.010
Low
17.00
Averages
18.86
High
23.00
Current: 18.010
Low
17.00
Averages
18.86
High
23.00
About KVUE
Kenvue Inc. is a consumer health company. The Company's differentiated portfolio of brands includes Aveeno, BAND-AID Brand, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee's, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women's health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Clorox's Rebuilding: After a $580 million ERP upgrade and a cyberattack, Clorox's $2.25 billion acquisition of GOJO Industries in 2026 is expected to drive sales growth over the next decade, particularly in hand hygiene products.
- Brown-Forman's Consistent Growth: With 42 consecutive years of dividend increases, Brown-Forman faces a soft global spirits market but has seen positive consumer engagement with its new Jack Daniel's Tennessee Blackberry flavor, projecting a 6% to 8% annual dividend growth over the next decade.
- Kimberly-Clark's Transformation: Currently undergoing its most significant transformation in 154 years, Kimberly-Clark reported a 3.7% increase in adjusted operating profit in Q1 2026 and reaffirmed its full-year guidance, indicating that restructuring is not disrupting core operations, while the merger with Kenvue will enhance market competitiveness over the next decade.
- Stable Dividend Yields: Clorox, Brown-Forman, and Kimberly-Clark offer dividend yields of 5.18%, 3.45%, and a safe level respectively, indicating that these companies will provide stable cash flow and potential capital appreciation for investors over the next ten years.
See More
- Church & Dwight's Strong Performance: Church & Dwight (CHD) achieved a 5% organic sales growth in Q1 2026, surpassing the 3% forecast, indicating the company's ability to navigate inflation through volume growth rather than price increases, thereby enhancing its market competitiveness.
- Keurig Dr Pepper's Growth Potential: Despite a nearly 29% decline from its 2025 peak, Keurig Dr Pepper (KDP) expects its energy drink portfolio to generate over $1 billion in annual retail sales, showcasing strong market demand and growth potential.
- Kenvue's Merger Prospects: Kenvue (KVUE) reported an 8.4% growth in its skin health and beauty division in Q1 2026, with quarterly sales reaching $1 billion, and the anticipated merger with Kimberly-Clark (KMB) is expected to further strengthen its market position and pricing power.
- Robust Investment Amid Market Uncertainty: In an uncertain market, these three companies provide a stable business foundation, making them suitable for investors looking to allocate $1,000 during turbulent times for long-term growth.
See More
- Stable Sales Growth: Church & Dwight achieved a 5% organic sales growth in Q1 2026, surpassing the 3% forecast, demonstrating its growth strategy focused on volume rather than price increases, which enhances its competitive edge in an inflationary environment.
- Acquisition to Expand Market Share: The company acquired the fast-growing stain-removal brand Miss Mouth's Messy Eater for $325 million, continuing its decade-long acquisition strategy aimed at expanding market share without increasing leverage, thereby solidifying its position in the consumer goods market.
- Energy Drink Portfolio Growth: Keurig Dr Pepper's energy drink portfolio is expected to exceed $1 billion in annual retail sales, and despite a 29% decline in stock price, its low double-digit adjusted earnings growth forecast indicates potential in the youth market, boosting investor confidence.
- Strong Performance in Beauty Health Segment: Kenvue's skin health and beauty division grew 8.4% in Q1 2026, reaching $1 billion in quarterly sales, reflecting stable consumer demand amid economic uncertainty, with the anticipated merger with Kimberly-Clark expected to further enhance market competitiveness.
See More
- Merger Catalyst: Kenvue's pending $40 billion merger with Kimberly-Clark is expected to transform it from a slow-growth spinoff into an efficient consumer goods powerhouse, with anticipated cost synergies of $2.1 billion, enhancing margins and accelerating growth.
- Strong Brand Portfolio: Kenvue owns trusted health products like Tylenol and Listerine, which maintain strong pricing power even during economic downturns, ensuring stable gross margins and consumer loyalty.
- Dividend Appeal: With a dividend yield of 4.53%, Kenvue is attractive to income-seeking investors, and this yield may increase post-merger, providing a buffer in volatile market conditions.
- Robust Financial Performance: Kenvue reported first-quarter revenue of $3.9 billion, a 4.5% year-over-year increase, with earnings per share of $0.25, up 47%, showcasing its strong position in the health consumer goods market and boosting investor confidence.
See More
- Historic IPO: SpaceX went public on June 12 at $135 per share, achieving an initial market value of $1.8 trillion, making it the largest IPO in history, with a first-day stock surge of over 20%, pushing its valuation above $2 trillion, indicating strong market expectations for its future potential.
- First-Year Performance Risk: Historical data suggests that large IPOs typically underperform in their first year, with SpaceX's stock potentially declining by 50%, implying that a $10,000 investment could drop to about $4,000 by 2027, reflecting concerns over its high valuation.
- Valuation Warning: With a current market value of $2.2 trillion and sales of $19.3 billion, SpaceX's stock trades at an exorbitant valuation of approximately 115 times sales, significantly higher than Palantir's 59 times, indicating that such a premium is unsustainable and could lead to future price corrections.
- Market Prospects and Challenges: While SpaceX has unique advantages in building orbital AI data centers, its high valuation and the general caution surrounding large IPOs create uncertainty regarding its future growth, necessitating careful risk-reward assessments by investors.
See More
- Historic IPO: SpaceX went public on June 12 at $135 per share, achieving a market value of $1.8 trillion, making it the largest IPO in history, with a first-day stock gain of over 20%, pushing its valuation above $2 trillion, reflecting high market expectations for its future potential.
- Valuation Risks: With a market value of $2.2 trillion and sales of $19.3 billion, SpaceX's stock trades at an exorbitant 115 times sales, significantly higher than the S&P 500's highest at 59 times, indicating a substantial bubble risk that could lead to major losses for investors.
- Historical Performance Warning: Historical data shows that the average stock price of the 15 largest IPOs has dropped by 33% in the first year; if SpaceX follows this trend, its stock could decline by 50% within the first year, reducing a $10,000 investment to below $5,300 by 2027.
- Market Prospects and Challenges: While SpaceX has a unique advantage in building orbital AI data centers that could effectively address power and cooling issues faced by terrestrial data centers, its high valuation and uncertain market performance necessitate cautious evaluation of its long-term investment value.
See More









